Clinical Trials
Pipeline
Product Candidate
Monotherapy / Combination
Indication
NP-G2-044
(Oncology)
Chemotherapy Agents
Ovarian Cancer
Pre-Clinical
Phase 1
Phase 2a
Phase 2B/3
Product Candidate
Monotherapy / Combination
Indication
NP-G2-044
(Oncology)
PD-1 Inhibitors
Solid Tumors
Pre-Clinical
Phase 1
Phase 2a
Phase 2B/3
Product Candidate
Monotherapy / Combination
Indication
NP-G2-044
(Oncology)
Monotherapy
Gynecological Tumors
Pre-Clinical
Phase 1
Phase 2a
Phase 2B/3
Product Candidate
Monotherapy / Combination
Indication
NP-G2-044
(Oncology)
Monotherapy
Thyroid Cancer
Pre-Clinical
Phase 1
Phase 2a
Phase 2B/3
Product Candidate
Monotherapy / Combination
Indication
NP-G2-044
(Oncology)
Monotherapy
Breast Cancer
Pre-Clinical
Phase 1
Phase 2a
Phase 2B/3
Product Candidate
Monotherapy / Combination
Indication
NP-G2-044
(Oncology)
Monotherapy
Hemotological Malignancies
Pre-Clinical
Phase 1
Phase 2a
Phase 2B/3
Product Candidate
Monotherapy / Combination
Indication
NP-G2-044
(Other Disease Areas)
Monotherapy
Infectious Diseases
Pre-Clinical
Phase 1
Phase 2a
Phase 2B/3
Product Candidate
Monotherapy / Combination
Indication
NP-G2-044
(Other Disease Areas)
Monotherapy
Neurological Degenerative Diseases
Pre-Clinical
Phase 1
Phase 2a
Phase 2B/3
Product Candidate
Monotherapy / Combination
Indication
Pre-Clinical
Phase 1
Phase 2
Phase 2B/3
NP-G2-044
(Oncology)
Chemotherapy Agents
Ovarian Cancer
PD-1 Inhibitors
Solid Tumors
Monotherapy
Gynecological Tumors
Thyroid Cancer
Breast Cancer
Hemotological Malignancies
NP-G2-044
(Other Disease Areas)
Monotherapy
Infectious Diseases
Neurological Degenerative Diseases
Phase 1 Clinical Trial
A Phase 1 clinical trial was conducted at 3 U.S. centers: City of Hope; Honor Health; and Memorial Sloan Kettering Cancer Center. The trial enrolled late-stage treatment-refractory patients with advanced/metastatic solid tumor malignancies and treated them in 6-week cycles (4-weeks on plus 2-weeks off). Seven orally bio-available dose cohorts were evaluated as monotherapy (200, 400, 600, 900, 1200, 1600, 2100 mg QD).
There were no Dose Limiting Toxicities (DLTs) and no drug-related Serious Adverse Events (SAEs). Tumor regressions were observed in multiple pre-treated refractory solid tumor patients and signals of efficacy observed in 100% (4 out of 4) metastatic gynecologic cancer patients (79% increase in median progression-free survival (PFS) compared to prior treatment and no new metastases for up to 8.5 months while on NP-G2-044 treatment).
Phase 2A Trial
- The monotherapy arm has been completed, and there were no DLTs or drug-related SAEs observed.
- The Immuno-oncology (IO) combination is currently in progress.
© 2023 Novita Pharmaceuticals, Inc. | Site Design by Digital Elevator